Table 2. Clinical and pathologic characteristics of Grade 3 endometrioid ECs by POLE mutation status.

	POLE mutation	POLE Wild type	p-value *
N	7	65
Age (median, min-max)	58.3 (55.2-87.3)	66.5 (44.3-90.7)	0.20
Race			0.99
White	6 (85.7)	55 (84.6)
Black	1 (14.3)	10 (15.4)
BMI (median, min-max) ˆ	25.8 (18.7-54.2)	32.3 (19.5-58.2)	0.18
High stage			0.41
Advanced stage (III/IV)	1 (14.3)	23 (35.9)
Early stage (I/II)	6 (85.7)	41 (64.1)
Deep myometrial invasion	5 (83.3%)	28 (49.1%)	0.20
(≥50%)ˆˆ
Presence of LVSI	4 (57.1%)	45 (71.4%)	0.42
Adjuvant therapy (any)	2 (28.6%)	39 (60.0%)	0.13

EC: endometrial cancer; BMI: body mass index; LVSI: lymphovascular space invasion.

^*P-values calculated by Fisher's Exact test for categorical variables and by Wilcoxon rank-sum test for continuous variables.

^ˆAvailable for 63 participants (58 POLE WT and 5 POLE mutation).

^ˆˆAvailable for 63 participants (57 POLE WT and 6 POLE mutation).